SCHEMBL4834840

SCHEMBL4834840

COC(=O)c1ccc(OCCNC(=O)C=C(C)c2cc3ccccc3o2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
HPGD P15428 2/20 0.57
MAPT P10636 8/20 0.47
RAB9A P51151 5/20 0.47
KDM4E B2RXH2 2/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
NPC1 O15118 4/20 0.46
CASP3 P42574 2/20 0.46
SENP7 Q9BQF6 2/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
POLB P06746 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 3/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL443883 0.90 SMN1; SMN2 (0.58) TSHRSMN1; SMN2HPGDMAPTRAB9A
SCHEMBL443882 0.90 SMN1; SMN2 (0.58) TSHRSMN1; SMN2HPGDMAPTRAB9A
SCHEMBL443884 0.90 SMN1; SMN2 (0.58) TSHRSMN1; SMN2HPGDMAPTRAB9A
SCHEMBL4252299 0.89 HPGD (0.53) TSHRSMN1; SMN2HPGDMAPTKDM4E
SCHEMBL4828371 0.89 TSHR (0.53) TSHRSMN1; SMN2HPGDMAPTRAB9A
SCHEMBL4248042 0.89 HPGD (0.53) TSHRSMN1; SMN2HPGDMAPTKDM4E
SCHEMBL4839715 0.85 SMN1; SMN2 (0.49) TSHRSMN1; SMN2HPGDMAPTRAB9A
SCHEMBL4833967 0.84 TSHR (0.48) TSHRSMN1; SMN2HPGDMAPTRAB9A
SCHEMBL14917735 0.81 HDAC4 (0.49) TSHRSMN1; SMN2HPGD
SCHEMBL14917734 0.81 HDAC4 (0.49) TSHRSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368476-B2 Hydroxamates as therapeutic agents PHARMACYCLICS, INC. (US) 2008-05-06 US disclosed
WO-2005097770-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2005-10-20 WO disclosed
US-20050227976-A1 Novel hydroxamates as therapeutic agents AXYS PHARMACEUTICALS, INC. (US) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227976-A1 Novel hydroxamates as therapeutic agents HDAC1, HDAC5, HDAC10 TSHR 3505/4885SMN1; SMN2 2607/4885HPGD 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.